Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials ...

Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials ...

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish ...

Novo won the U.S. Food and Drug Administration's approval in 2024 to use Wegovy to reduce the risk of cardiovascular death, ...

Robbie Williams' concerns over weight-loss injections potentially harming his eyesight have sparked widespread worry. While ...

Novo's upcoming Alzheimer's trial results will test whether Rybelsus can slow cognitive decline and reshape treatment ...

The oral version of Rybelsus failed to meet its primary goal in two late-stage clinical trials, which aimed to evaluate its ...

Such conversations are becoming increasingly common as demand for weight-loss drugs explodes in urban India - a country with the world's second-largest number of overweight adults and more than 77 ...

Middle-class Indians trying to lose weight are embracing drugs such as Mounjaro in a country that has been called the world’s diabetes capital.

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...